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Summary Background: The efficacy of chemotherapy in metastatic and recurrent squamous cell carcinomas of the head and neck (HNSCC) remains unsatisfactory. Gefitinib offers a new therapeutic option with comparable results and better tolerability than chemotherapy. We conducted this study to see if mutations in the epidermal growth factor receptor (EGFR) might predict the therapeutic benefit in HNSCC patients. Patients and Methods: In a pilot trial, 8 patients with metastatic or recurrent HNSCC were treated palliatively with gefitinib (500 mg/day orally). Forceps biopsies were taken to confirm tumor recurrence and to perform an EGFR mutation analysis. Results: The EGFR status could be determined in 6 of the 8 patients. 5 patients had no EGFR gene mutation, and 1 patient showed a silent guanine-to-adenosine mutation in position 2607. Even without any relevant mutation in the EGFR, we observed partial remission in 3 of 6 patients treated with gefitinib. We also observed that an additional 4 patients had stable disease for at least 10 weeks. The median progression-free survival was 6.25 months, and the median overall survival was 7.39 months. Conclusion: In HNSCC, there are tumor responses to gefitinib without protein-altering mutations in the EGFR gene.
Introduction
Thesurvivalratesofpatientswithsquamouscellcarcinomaof theheadandneck(HNSCC)havenotmuchimprovedover the last decade [1] . Curative approaches are in competition with their functional and cosmetic outcomes, which significantlyinfluencethepatient'squalityoflife [2] .Abouthalfof thetreatedpatientswillrelapselocallyorwithdistantmetastases.ThetreatmentofrecurrentandmetastaticHNSCCisa major therapeutic challenge. The prognosis of patients with recurrentormetastaticHNSCCisgenerallypoor,withamediansurvivalofabout6months [3] .Patientsingoodgeneral conditionandwithlocallyrecurrentdiseasecanbenefitagain fromeithersurgeryorfurtherradiotherapy [4] .Forpatients withmetastaticorunresectablerecurrentdiseasewithoutthe option for re-irradiation, conventional chemotherapy or targetedagentsaretheonlytreatmentoptions.
The response rates with conventional chemotherapeutic agents generally reach 15-30% with a response duration of 3-5months [5] [6] [7] .Severalrandomizedtrialshaveshownthat combination chemotherapy showed a higher response rate, butthiscomesatthepriceofincreasedtoxicityandwithout any significant survival advantage [8] . It has recently been shown for the first time that, in addition to conventional chemotherapy,atargetedagentagainsttheepidermalgrowth factor receptor (EGFR), cetuximab, significantly improves themedianoverallsurvival(OS)by2.5months [9] .However, in second-line therapy, the response rates are minimal. In a multi-institutionalretrospectiveanalysisof151patientswith progressive cancer following treatment with platinum-based therapy,theoverallresponseratewas2.6%,andthemedian timetotumorprogressionwithbestsupportivecare,chemotherapy, radiotherapy, and radiochemotherapy was 45, 67, 131,and153days,respectively [10] .Noveltherapeuticstrategiesareurgentlyneeded. TheEGFRisoverexpressedinupto90%ofHNSCCcases [11] [12] [13] . Malignant cells express 50-100 times more EGFR thannormalkeratinocytes [14] .Often,overexpressionofthe EGFR is associated with an increased production of EGFR ligands,whichresultsinanautocrinestimulationofthetumor cells [15] .ThisautocrinesignalingofEGFandEGFRmaybe blockedbyEGFRantibodieslikecetuximaborothersmallmoleculeinhibitorsoftheEGFRtyrosinekinase-1 [16] .One of these small-molecule inhibitors is gefitinib, a synthetic anilinoquinazoline.GefitinibistakenorallyandactstoselectivelyinhibittheEGFRtyrosinekinase [17] .Invitroandin vivo preclinical studies in tumor cell lines in mice showed a dose-dependent anti-proliferative effect of gefitinib [18] . As monotherapies, the EGFR inhibitors have modest overall activity with response rates of 1-11% for gefitinib [19] and erlotinib [20] .However,comparedtoaconventionalchemotherapy regimen with methotrexate, gefitinib showed equal survivalratesbutfewersideeffects [7] .
Fromtheexperiencewithnon-small-celllungcancer,itis known that the response rates to gefitinib in an unselected patient population are disappointingly small [21] . However, some patients showed a tumor response that has not been previously observed in treatment with conventional chemotherapy.Inalandmarkstudy,Lynchetal. [22] wereableto demonstrate that 8 of 9 patients with gefitinib-sensitive adeno carcinomas of the lung had a somatic mutation in the tyrosinekinasedomainoftheEGFRwhilenomutationswere found in gefitinib-resistant cancers. The mutations detected were either small in-frame deletions or amino acid substitutions that accumulated near the ATP binding site of the tyrosinekinasedomain.
Theaimofthisstudywastodeterminewhetherthereisa correlationbetweenthetumorresponseofHNSCCtotreatment with gefitinib and alterations in the EGFR. If so, the possibilitymightexistforamoretargetedapproachtotreat HNSCCwithgefitinibandimproveitstherapeuticefficacy.
Patients and Methods
Inthispilottrialattheinterdisciplinaryheadandneckcancercenterof theBaselUniversityHospital,8patientswithHNSCCwereenrolled.The protocolwasapprovedbytheethicalcommitteeofBasel(EKBB97/03). Patientswithrecurrentandunresectablelocoregionaland/ordistantmetastatic HNSCC with either progressive disease after at least 1 prior chemo therapyorchemoradiotherapyregimenorpatientswithnobetter treatmentoptionswereeligibleforthetrial.Eligibilitycriteriaincludeda life expectancy > 3 months, an Eastern Cooperative Oncology Group (ECOG)performancestatus(PS)of≤2,andadequatehematologic,renal and liver function. Exclusion criteria included significant comorbidities (includingcoronaryarterydisease,symptomaticcongestiveheartfailure, activealcoholabuse,bleedingdiathesis,historyofinterstitiallung disease, orgastrointestinalulcerwithin12months);concurrentuseofphenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John's wort;orsurgeryorradiotherapywithin30days. TreatmentwithgefitinibwasprovidedfreeofchargebyAstraZeneca as part of a compassionate use program. The planned regimen recommended that gefitinib be administered orally at a dose of 250 mg twice dailywithinatreatmentcycleof28days.
Tumor assessment for response took place at the end of every 2nd cycle(i.e.,8weeks)oftherapy.Inpatientscompleting6cyclesoftherapy, the evaluation for response was performed after every 3rd cycle. ResponsewasassessedradiographicallyaccordingtotheResponseEvaluation Criteria in Solid Tumors (RECIST) [23] and by physical examination.Patientswithatleaststabledisease(SD)continuedtreatmentwith gefitinibuntileithertumorprogressionorunacceptabletoxicityoccurred. Allpatientsweredeadatthetimeofanalysis.Progression-freesurvival (PFS) and OS were estimated from the start of therapy until disease progressionordateofdeath. EGFRMutationAnalysisinHNSCC beforeGefitinibTreatment 163 treatedwith500mg/dayofgefitinibfor73days(range0-258 days) and with 250 mg/day of gefitinib for 116 days (range 0-268 days). The average cumulative total dose was 65.9 g (range 10.7-129 g). The average cumulative total dose obtainedwas69%oftheexpectedtotaldose,whichwasequivalenttoadosereductionof31%.Reasonsfordiscontinuationincludedtumorprogression(2/8),death(4/8),andside effects (2/8). 6 patients received no further treatment after gefitinib,1patientreceivedchemotherapywithcisplatinand 1patientreceivedchemotherapywithdocetaxel,radiotherapyandbisphosphonatetreatmentafterstoppinggefitinib.
Method of EGF Receptor Mutation Analysis
Side Effects of Gefitinib Therapy
The most common side effects of gefitinib therapy were varyingdegreesofskinrashanddiarrhea.6patientshadskin rashes greater than grade 2, and 2 patients had diarrhea greaterthangrade2.Becauseofthesesideeffects,gefitinib therapywaseitherinterruptedforvariousdurationsoftime oradosereductionto250mg/daywasmade.Aftertheintroduction of these measures, a decline in side effects was observedinallpatients,andtreatmentcouldbecontinuedin RNA Isolation Total RNA was extracted using the optimized TRIZOL ® reagent (Invitro gen). For this purpose, we followed the protocol of the RNeasy ® MicroKitforRNApurification,whichincludedon-columnDNasetreatmenttoeliminategenomicDNAinthesamples.
Reverse Transcription
Forthereversetranscription(RT)ofmRNA,200ngoftotalRNAwas mixed in a volume of 7 ml with 3 mM dT25 primer. To perform the annealing,theRNAanddT25primerwerekeptfor10minat65°Cand then immediately cooled on ice. The cDNA synthesis was carried out withthehelpof1ml(100U)ofSuperScript ® reversetranscriptaseMMLV (Boehringer) in 12 ml RT buffer (containing 200 mM dNTP, 10mMdithiothreitol(DTT)and40URNAsin1 ® (Boehringer))for1hat 42°C.ThecDNAwasstoredat-20°Cthereafter.
Polymerase Chain Reaction
To perform the polymerase chain reaction (PCR) for the amplification of exons 19-21 of the EGFR gene, the 18-mer primer EGFR-1 (GeneID: 1956, Consensus CDS: CCDS5514.1) forward (GCTT-GTGGA GCCTCTTAC) and a 19-mer reverse primer (GGTGGG-TATAGATTCTGTG) were used. The PCR was carried out in a volume of 50 ml, which included the buffer and the enzyme from the Advantage Klen Taq KIT1 ® (Clontech). The reaction was carried out with 1 mM of primers, 10 mM dNTP and 5 ml RT product as the template. For amplification, the following cycling protocol was used: 15sat94°C,30sat63°C,and30sat72°C,for35cycles.
Sequencing of PCR Products
The sequencing of the PCR fragments was carried out after the cycle sequencing protocol and subsequent capillary electrophoresis according tothestandardprotocolofMicrosynthAG(Balgach,Switzerland).When sequencing,the21-merprimerGGAGCCTCTTACACCCAGTGGwas used. The sequences were compared with the wild-type EGFR gene sequenceusingtheBlastprogram.
Results
Patient Characteristics
HNSCCwasconfirmedinallpatientsbyeithercytologyor histology.TheinitialdiagnosiswasestablishedbytheInstitute of Pathology within the University of Basel between 1999and2003.Thepatientcharacteristicsaregivenintable1. Overall, the patients represented a population of mostly heavily pretreated patients who had either recurrent or metastaticdisease.
The Gefitinib Therapy
Patients received a total of 53 cycles of treatment (median 7 cycles, range 1-12 cycles). 4 patients were treated with 500mgofgefitinibdaily.In2ofthesepatients,thedosehad to be reduced to 250 mg/day due to side effects during the course of the disease. In the other 2 patients, the full dose was used until discontinuation due to tumor progression occurred on days 78 and 258, respectively. The 4 other patientsweretreatedwith250mgofgefitinibfromthebegin-ningofthestudy;adosereductionwasnevernecessary.The average duration of gefitinib therapy without a break was 190 days (range 43-333 days). On average, patients were 
Discussion
In non-squamous-cell lung cancer, mutations in the EGFR geneoccuratarelativelyhighfrequency [24] ,butwehavenot found any mutations in the EGFR in our HNSCC patients. Today, in lung cancer, EGFR mutations are accepted as predictivemarkersofthebenefitofgefitinibtherapy [25, 26] .
There is a significant superiority of gefitinib in patients bearingtumorswithanEGFRmutationandaninferiorityof gefitinibtoconventionalchemotherapyinnon-mutatedcancers. For HNSCC, we cannot confirm this result previously derivedfromlungcancer.Inourpilotstudy,wedidnotfind anyrelevantmutationsintheEGFRalthoughweobserveda response rate of 37.5%. The absence of EGFR mutations is consistentwiththedataofLoeffler-Raggetal. [27] whoobservedonly1mutationin100casesofHNSCC.Additionally, aSpanishstudy(31patients),astudyfromJapan [28] anda study from Minneapolis (20 patients) did not identify any mutationsinHNSCC [29] patients. Similartoourtrial,thephaseIIstudybyCohenetal. [19] demonstrated an objective response rate of 11% in patients withrecurrentandmetastaticHNSCCwhoweretreatedwith 500mg/dayofgefitinib.InthestudybyKirbyetal. [30] ,itwas observed that gefitinib was well tolerated and resulted in symptomaticimprovementinone-thirdofthepatients.
Similarly,theaveragePFSof6.25(minimum1.3/maximum 10.8) months in our trial is in agreement with the previous studies. The median PFS and OS were 1.8 and 5.5 months, respectively,inthestudybyCohenetal. [31] with250mg/day of gefitinib, whereas they were 3.4 and 8.1 months, respectively, with 500 mg/day of gefitinib [19] . With an OS of 7.4 (minimum4.1/maximum10.8)months,ourresultsareinthe samerange.Thequalityoflifeofthepatientsimprovedtemporarilyduringthefirstweeksoftherapy.Inourstudy,50% ofthepatients(4of8)hadaPFSoflongerthan200days,and theaveragePFSwas180daysinallpatientsanalyzed.
Besides the retrospective study of Murray et al. [32] who analyzed 19 tumor specimens from patients treated with gefitinib,ourtrialistheonlyonetoanalyzetheEGFRmutationstatusinacohortofpatientstreatedwithgefitinib.Thus, evenwithoutamutationintheEGFR,thereisanobjective response to gefitinib in HNSCC. There are, of course, some limitations to the interpretations being derived from this study,duetothesmallnumberofpatientsanalyzed.Whilewe cannotexcludethatsomerarepatientswithanEGFRmutationwouldbenefitevenmorefromgefitinib,wedemonstrated all but 1 patient who died due to tumor progression soon afterthedosereduction.
Results of Gefitinib Therapy
Thetumorresponseevaluationwascarriedoutaccordingto theRECISTcriteria.3patientshadapartialresponse(PR), 4 patients had SD, and 1 patient had progressive disease (PD)( fig.1).ThemedianPFSwas6.25months(range1.3-10.8 months) . The median OS was 7.4 months (range 4.1-10.8months).The3patientswithoutpriorsystemictherapy hadaPFSof2.6,5.8,and10.8months,respectively,whichis inthesamerangeasforthepatientspreviouslytreatedwith chemotherapy.
Results of the EGF Receptor Mutation Analysis
In6of8patients,anEGFRmutationanalysiscouldbeperformed(75%).5patientshadnomutationinthesequenced part of exons 19-21, and 1 patient had a silent guanine-toadenosinemutationinposition2607.Intheother2patients, no sequence was obtained ( [33] . However, other EGFR/ErbB receptor family members may contributetoresistancetogefitinib [34] .Inagenomicanalysis, tumor cell line markers associated with epithelial-mesenchymal transition have been associated with resistance to gefitinib [35] .Aproteomicanalysiscorrelatedgefitinibsensitivity with p-AKT and p-STAT3 activation in HNSCC cell lines and tumor specimens, which implies that p-AKT and p-STAT3 could serve as potentially useful biomarkers and drug targets [36] . Wheeler et al. [37] analyzed c-myc and cyclinD1aspredictorsforgefitinibtherapy.10pairedtumor samplesweretestedbyRT-PCRforc-mycandcyclinD1gene expression.Nocorrelationwasfoundbetweenchangesinthe expressionofthesegenesandtheclinicalbenefitofgefitinib. EGFRvIII has been proposed as a marker of resistance to therapy with cetuximab [38] ; its role as a predictive marker forgefitinibiscurrentlyunknown.Insummary,thereiscurrently no reliable predictive marker identified for gefitinib therapyinHNSCC,andtheestablishmentofsuchamarkeris stillaclinicalneed.
Conclusion
InHNSCC,EGFRmutationanalysisseemsnottobehelpful inthepredictionofbenefitfromgefitinib.Thus,thereisstilla need to identify other factors influencing the response to gefitinib.
